Abiopharma

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Edgewise Therapeutics - Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

DVAX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Dynavax Technologies Corporation is Fair to Shareholders

BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program

Medi Lifestyle - Announcement

OUE Healthcare Limited - Announcement

Changes To The Composition Of The Board Of Directors And The Nominating And Remuneration Committee

Change - Announcement Of Cessation :: Resignation Of Non-Independent And Non-Executive Director